IGF1R and neoplasm: Additionally, increased IGF-1R signaling was observed in AXL-low mtEGFR-expressing NSCLC tumor cells treated with osimertinib and knockout of IGF-1R sensitized AXL-low NSCLC cells to osimertinib, suggesting that IGF-1R drives cell survival in the presence of osimertinib [241].